Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
Location: United States, Pennsylvania, Philadelphia
Employees: 51-200
Total raised: $410M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | Octagon Ca... | octagoninv... |
| - | RA Capital... | racap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.03.2021 | Series C | $160M | - |
| 01.07.2019 | - | $250M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Daniel | Geffken | Senior Fin... | linkedin.c... | - | - |